<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                           September 16, 2024

John W. Gamble, Jr
Chief Financial Officer
Equifax Inc.
1550 Peachtree Street, N.W.
Atlanta, GA 30309

       Re: Equifax Inc.
           Form 10-K for the Fiscal Year Ended December 31, 2023
           File No. 001-06605
Dear John W. Gamble Jr:

       We have reviewed your filing and have the following comment.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe
the comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Annual Report on Form 10-K for fiscal year ended December 31, 2023
Item 1C. Cybersecurity, page 26

1.     We note your senior leadership team consisting of your CEO and his
direct reports (SLT)
       is responsible for setting the tone for strategic growth, effective
operations and risk
       mitigation at the management level, as well as, the overall managerial
       responsibility for confirming that the information security program
functions in a manner
       that meets the needs of Equifax. We also note that you described the
relevant expertise of
       your CISO but not of the other members of the SLT. Please revise future
filings to discuss
       the relevant expertise of such members of senior management as required
by Item
       106(c)(2)(i) of Regulation S-K.
        We remind you that the company and its management are responsible for
the accuracy and
adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action
by the staff.

      Please contact Pearlyne Paulemon at 202-551-8714 or Sebastian Gomez Abero
at 202-
551-3578 with any questions.
 September 16, 2024
Page 2



                     Sincerely,

                     Division of Corporation Finance
                     Office of Life Sciences
cc:   John Kelly
</TEXT>
</DOCUMENT>
